menu
    • menu
    [{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Fuji Pharma"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alvotech

                            Iceland arrow
                            ESCRS
                            Not Confirmed

                            Alvotech

                            Iceland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Advanz Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech and Advanz Enter into Supply and Commercialization Agreement for AVT10

                            Details : The agreement aims for the supply and commercialization of AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Advanz Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alvotech

                            Iceland arrow
                            ESCRS
                            Not Confirmed

                            Alvotech

                            Iceland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Advanz Pharma

                            Deal Size : $343.4 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe

                            Details : Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar c...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $60.1 million

                            May 24, 2023

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Advanz Pharma

                            Deal Size : $343.4 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alvotech

                            Iceland arrow
                            ESCRS
                            Not Confirmed

                            Alvotech

                            Iceland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Fuji Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan

                            Details : The new agreement adds another biosimilar candidate to the partnership between Alvotech and Fuji, first announced in 2018, bringing the total number of proposed biosimilar products that the companies are partnering on to six.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 23, 2022

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Fuji Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth